| Title: |
Associations between change in BMI and the risk of hypertension and dyslipidaemia in people receiving integrase strand-transfer inhibitors, tenofovir alafenamide, or both compared with other contemporary antiretroviral regimens: a multicentre, prospective observational study from the RESPOND consortium cohorts |
| Authors: |
Byonanebye D. M.; Polizzotto M. N.; Maltez F.; Rauch A.; Grabmeier-Pfistershammer K.; Wit F.; De Wit S.; Castagna A.; d'Arminio Monforte A.; Mussini C.; Wasmuth J. -C.; Fontas E.; Abela I.; Sarcletti M.; Bansi-Matharu L.; Jaschinski N.; Peters L.; Hosein S. R.; Vannappagari V.; Cohen C.; Bissio E.; Mocroft A.; Law M.; Ryom L.; Petoumenos K. |
| Contributors: |
Byonanebye, D. M.; Polizzotto, M. N.; Maltez, F.; Rauch, A.; Grabmeier-Pfistershammer, K.; Wit, F.; De Wit, S.; Castagna, A.; D'Arminio Monforte, A.; Mussini, C.; Wasmuth, J. -C.; Fontas, E.; Abela, I.; Sarcletti, M.; Bansi-Matharu, L.; Jaschinski, N.; Peters, L.; Hosein, S. R.; Vannappagari, V.; Cohen, C.; Bissio, E.; Mocroft, A.; Law, M.; Ryom, L.; Petoumenos, K. |
| Publisher Information: |
Elsevier Ltd |
| Publication Year: |
2024 |
| Description: |
Background: Integrase strand-transfer inhibitors (INSTIs) and tenofovir alafenamide have been associated with weight gain in several clinical trials and observational cohorts. However, whether weight gain associated with INSTIs and tenofovir alafenamide confers a higher risk of weight-related clinical events is unclear. We aimed to assess whether changes in BMI differentially increase hypertension or dyslipidaemia risk in people with HIV receiving INSTIs, tenofovir alafenamide, or both versus other contemporary regimens. Methods: This multicentre, prospective observational study analysed prospective data from RESPOND, an international consortium of HIV cohorts for which recruitment began in 2017 and is still ongoing from HIV clinics and hospitals in 37 European countries and Australia. Participants were eligible if they were aged 18 years or older, receiving INSTI-containing antiretroviral therapy (ART) regimens or a contemporary non-INSTI, did not have hypertension or dyslipidaemia at baseline, and had baseline and at least two follow-up BMI, lipid, and blood pressure measurements. We excluded participants without baseline CD4 or HIV RNA results and those receiving non-ART medications associated with weight changes, including antipsychotics and mood stabilisers, corticosteroids, insulin, and insulin secretagogues. They were followed up from baseline until the earliest hypertension or dyslipidaemia event, their last visit, or Dec 31, 2021, whichever was earlier. The primary outcomes were incidence of hypertension and dyslipidaemia, for which we used multivariable Poisson regression adjusted for time-updated BMI to determine unadjusted and adjusted incidence rate ratios (IRRs) of hypertension and dyslipidaemia in people receiving INSTIs, tenofovir alafenamide, or both, and tested for interaction between time-updated ART regimen and BMI. Findings: Of the 35 941 RESPOND participants, 9704 (7327 [75·5 %] male and 2377 [24·5%] female) were included in the hypertension analysis and 5231 (3796 [72·6%] male and 1435 ... |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| Relation: |
info:eu-repo/semantics/altIdentifier/wos/WOS:001238130900001; volume:11; issue:5; firstpage:321; lastpage:332; numberofpages:12; journal:THE LANCET. HIV; https://hdl.handle.net/20.500.11768/198758 |
| DOI: |
10.1016/S2352-3018(23)00328-4 |
| Availability: |
https://hdl.handle.net/20.500.11768/198758; https://doi.org/10.1016/S2352-3018(23)00328-4 |
| Accession Number: |
edsbas.85ED3C5D |
| Database: |
BASE |